London, UK – January, 2026 – Bien-Etre Ltd today announced the appointment of Dr. Jin-Xiong She to its Advisory Board as Chief Medical Advisor.
Dr. Jin-Xiong She brings extensive expertise in cellular health optimization and longevity medicine to Bien-Etre’s mission of delivering diagnostic-first health solutions. His research focuses on NAD+ metabolism, mitochondrial function, and the cellular mechanisms underlying health span extension. With a distinguished career spanning clinical practice and academic research, Dr. She has published extensively on biomarkers of aging and interventions that target cellular senescence and metabolic decline.
“Dr. She’s commitment to expanding health-span perfectly aligns with our evidence-based approach at Bien-Etre,” said Aly Rahimtoola, Founder & CEO of Bien-Etre. “His dedication to rigorous science and measurable outcomes is reflected in his commitment to supporting our platform as we scale precision wellness across the GCC region.”
In his advisory role, Dr. She will guide Bien-Etre’s clinical protocols, oversee the scientific integrity of its NAD+ optimization programs, and contribute to the development of its epigenetic analysis and longevity assessment technologies.
“I am very happy to be joining Bien-Etre’s Advisory Board and assisting the team with the development of longevity protocols and optimization in the GCC region. The importance of preventative health and wellness is a fundamental and vital development to the health and wealth of the region and I look forward to working with the team and Bien-Etre’s partners.” said Dr Jin-Xiong She.
Bien-Etre operates as a “Longevity-as-a-Service” platform, offering intracellular NAD+ testing and various AI-driven concierge tools for corporate and individual clients across the GCC.
